MiNK Therapeutics, Inc.

INKT

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001840229

SEC filings (opens in a new tab)

No open-market purchases or sales by MiNK Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.39M in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding MiNK Therapeutics, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021 All holders in Q3 2021

13F holders of INKT: Q3 2021 compared with Q4 2021
Measure	Q3 2021	Q4 2021	Change
Holders	0	21	+21
Shares	0	1.34M	+1.34M
Value	$0	$5.96M	+$5.96M

New holders (21)

Institutions that held MiNK Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to INKT in Q4 2021
Institution	Shares	Value	% of portfolio
RTW Investments, LP	416,666	$1.86M	0.03%
Sofinnova Investments, Inc.	345,499	$1.54M	0.10%
Artal Group S.A.	289,588	$1.29M	0.04%
Millennium Management LLC	68,509	$306.0K	0.00%
Morgan Stanley	42,570	$189.0K	0.00%
Gyon Technologies Capital Management, LP	42,448	$189.0K	0.03%
Renaissance Technologies LLC	35,100	$157.0K	0.00%
Geode Capital Management, LLC	23,575	$105.0K	0.00%
Invesco Ltd.	21,066	$94.0K	0.00%
State Street Corp	11,929	$53.0K	0.00%
Vanguard Group Inc	10,771	$48.0K	0.00%
BlackRock Inc.	10,399	$46.0K	0.00%
New York State Common Retirement Fund	8,000	$36.0K	0.00%
UBS Group AG	3,934	$18.0K	0.00%
Bank of America Corp	1,847	$8.00K	0.00%
Tower Research Capital LLC (TRC)	1,826	$8.00K	0.00%
American International Group, Inc.	1,037	$5.00K	0.00%
Wells Fargo & Company	1,207	$5.00K	0.00%
Citigroup Inc	909	$4.00K	0.00%
Royal Bank of Canada	485	$2.00K	0.00%
Ameritas Investment Partners, Inc.	150	$1.00K	0.00%

Sold out (0)

Institutions that held MiNK Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.

None.